Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151815 | 0.86 | GRIN2B (0.68) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL6151725 | 0.85 | GRIN2B (0.50) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL6690779 | 0.85 | GRIN2B (0.50) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL6152148 | 0.85 | GRIN2B (0.50) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL6152306 | 0.83 | OPRL1 (0.54) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL8857324 | 0.80 | OPRL1 (0.51) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL7330603 | 0.79 | OPRL1 (0.50) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL6816851 | 0.79 | ABCB1 (0.45) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL6690805 | 0.79 | GRIN2B (0.44) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL6811437 | 0.78 | OPRM1 (0.44) | OPRL1OPRM1OPRK1OPRD1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743921-B2 | HYDROGENATION OF A CORRESPONDING NONRACEMIC 1-(4-BENZOXY PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANONE USING A CATALYST SYSTEM COMPRISING RUTHENIUM, A NONRACEMIC DIPHOSPHINE LIGAND, A BIDENTATE AMINE LIGAND SELECTED FROM | DSM CATALYTICA PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | claimed |
| US-20030144521-A1 | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl -piperidin-1-yl)-1-propanol compounds | DSM CATALYTICA PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003062180-A1 | PROCESS FOR THE PREPARATION OF NONRACEMIC SYN-1-(4-HYDROXY-PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANOL COMPOUNDS | DSM N.V. (NL) | 2003-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144521-A1 | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl -piperidin-1-yl)-1-propanol compounds | SYNJ1, HRH4, HRH3 | OPRL1 1447/4885OPRM1 584/4885OPRK1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.